7.2 C
New York
Tuesday, December 5, 2023

Is Avidity Biosciences Inc (NASDAQ: RNA) The Best Stock To Invest In?

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for Avidity Biosciences Inc (RNA) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.02, or -0.36%, to $5.46. The Avidity Biosciences Inc has recorded 160,043 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Stocks Info

Avidity Biosciences Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $5.48 and fluctuated between $5.60 as its day high and $5.16 as its day low. The current market capitalization of Avidity Biosciences Inc is $406.07M. A total of 0.77 million shares were traded on the day, compared to an average of 789.65K shares.

Insider Activity

Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, RNA has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 12 BUYs and 8 SELLs from insiders. Insiders purchased 256,600 shares during that period but sold 110,100.

In the most recent transaction, LEVIN ARTHUR A sold 100 shares of RNA for 22.01 per share on Mar 15. After the transaction, the Director now owns 19,330 company shares. In a previous transaction on Feb 14, LEVIN ARTHUR A sold 10,000 shares at 23.66 per share. RNA shares that Chief Scientific Officer owns now total 19,330.

Among the insiders who sold shares, Boyce Sarah disposed of 3,221 shares on Feb 03 at a per-share price of $24.26. This resulted in the President and CEO holding 53,352 shares of RNA after the transaction. In another insider transaction, Boyce Sarah sold 45,879 shares at $24.36 per share on Feb 02. Company shares held by the President and CEO now total 53,352.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for RNA in the last 3 months, the mean price target is $37.00 with high estimates of $71.00 and low estimates of $18.00. In terms of 52-week highs and lows, RNA has a high of $25.74 and a low of $4.82.

As of this writing, RNA has an earnings estimate of -$0.77 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of -$0.73 per share and a lower estimate of -$0.8. The company reported an EPS of -$0.74 in the last quarter, which was 12.90% higher than expectations of -$0.85.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. RNA’s latest balance sheet shows that the firm has $405.54M in Cash & Short Term Investments as of fiscal 2021. There were $9.96M in debt and $29.66M in liabilities at the time. Its Book Value Per Share was $6.98, while its Total Shareholder’s Equity was $381.43M.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RNA is Buy with a score of 4.83.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles